Medical condition
Bladder Cancer
Bladder Cancer is a medical condition tracked by NovaPharmaNews across 4 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- durvalumab (IMFINZI) Antineoplastic and immunomodulating agents (L01)
- nadofaragene firadenovec (ADSTILADRIN) Antineoplastic and immunomodulating agents (L01)
- nogapendekin alfa inbakicept (ANKTIVA) Antineoplastic and immunomodulating agents (L03)
- sasanlimab (ZUMRAD) Antineoplastic and immunomodulating agents (L01)
Latest Bladder Cancer news
Advancing Bladder Cancer Care Through Education and Awareness
Bladder Cancer Awareness Month highlights ongoing challenges and progress in the field. Educational initiatives are crucial for optimizing treatment and improving patient outcomes.
AstraZeneca's Imfinzi Secures Second Bladder Cancer Approval
AstraZeneca's Imfinzi has gained a second approval for bladder cancer treatment, marking a significant milestone in its development. This article explores the implications for the pharmaceutical landscape.
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer
The FDA has approved Atezolizumab for muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options. This approval has important implications for investors and pharmaceutical teams.
Roche's ctDNA-Guided Approach in Bladder Cancer: A Strategic Win
Roche's innovative ctDNA-guided approach for Tecentriq in post-surgical bladder cancer has garnered significant attention. This article explores the implications for pharmaceutical teams and investors.
FDA Grants Priority Review to PADCEV-Keytruda Combination for Muscle-Invasive Bladder Cancer Treatment
Astellas receives FDA Priority Review for PADCEV plus Keytruda as first perioperative treatment for muscle-invasive bladder cancer regardless of cisplatin eligibility.